Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341306 | 0.87 | NPSR1 (0.43) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6351972 | 0.84 | MAPT (0.41) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6351289 | 0.82 | NPSR1 (0.40) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6351818 | 0.74 | BTK (0.37) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6340087 | 0.73 | MAPT (0.42) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6342923 | 0.72 | MAPT (0.42) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6342517 | 0.71 | HPGD (0.42) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6340217 | 0.71 | ALDH1A1 (0.44) | HSD17B10HPGDMAPK1KDM4EALDH1A1 | |
| SCHEMBL6339985 | 0.69 | L3MBTL1 (0.43) | HSD17B10HPGDMAPK1ALDH1A1 | |
| SCHEMBL6345281 | 0.69 | ALDH1A1 (0.46) | HSD17B10HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | HSD17B10 802/4885HPGD 19/4885MAPK1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.